|Partial Close, 11/2012 ||$8.49M|
|Series A, 11/2012 |
Boehringer Ingelheim Venture Fund
Mitsui Global Investment
ArmaGen® provides platform technology solutions to the ‘blood-brain barrier’ problem, and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain.